NZ Cannabis Export Licence Requirements (Post-July 2024)

The July 2024 amendments turned New Zealand from a closed market into an export-ready jurisdiction. The licence path is straightforward, but the sequencing matters.

An NZ cannabis export licence is the controlled drug export licence required for any cannabis seed, starting material, cannabis-based ingredient, or finished product leaving New Zealand. Without an NZ cannabis export licence in hand, no cannabis material may legally cross the border, regardless of the buyer’s import paperwork. The Medicinal Cannabis Agency (MCA) issues it under the Misuse of Drugs (Medicinal Cannabis) Regulations 2019, as amended on 5 July 2024 by the Amendment Regulations 2024 (SL 2024/129). This article walks through what the amendments changed, which licences you need, how the importing country fits into the workflow, and what quality standards now apply to exports.

For the broader regulatory picture, our complete NZ Medicinal Cannabis Compliance Checklist covers the full Scheme end to end, including the five licence activity types, GACP cultivation, GMP manufacturing, and the Minimum Quality Standard verification workflow.

What Changed with NZ’s July 2024 Cannabis Export Amendments?

The Misuse of Drugs (Medicinal Cannabis) Amendment Regulations 2024 (SL 2024/129) came into force on 5 July 2024 and rewrote the export rules in three material ways. Before the amendments, NZ exports were not commercially viable. After them, NZ is an export-ready jurisdiction with an estimated NZ$250 million market potential.

The three structural changes:

1. Quality standards for export reference the importing jurisdiction, not NZ MQS. Pre-amendment, every exported product had to meet the NZ Minimum Quality Standard before it could leave the country. Post-amendment, exports only need to satisfy the importing country’s quality standards. This is the biggest single operational change in the new framework. A producer shipping flower to Germany now meets EU GMP and the German pharmacopoeia, not NZ MQS.
2. Starting material definitions broadened. The amendments expanded what counts as exportable starting material, enabling NZ producers to supply seed, plant material, and cannabis-based ingredients to overseas testing, analysis, and research programs. Before the amendments this category was effectively closed.
3. Seed and material export for research enabled. Export of cannabis seed, starting material, and cannabis-based ingredients for testing, analysis, or research is now permitted under the controlled drug export licence regime. This opens collaboration with overseas universities, contract research organisations, and pharmaceutical partners.

Alongside the export expansion the amendments also introduced Regulation 38A, which bans personal importation of CBD products by overseas courier or mail. That is an import-side restriction, but it sits in the same instrument and should be flagged when explaining the overall import/export framework. Operators applying for a new NZ cannabis export licence after July 2024 inherit the looser export rules and the tighter personal-import ban together.

Which NZ Cannabis Export Licence Do You Need to Ship Cannabis Material Overseas?

For an NZ cannabis export licence you need a controlled drug export licence covering the specific cannabis material you intend to ship. The NZ cannabis export licence is consignment-specific and tied to a named overseas consignee, not an open-ended permission to export. The licence is issued by the MCA under the Misuse of Drugs Regulations and applies to all cannabis material categories.

What requires a controlled drug export licence:

• Cannabis seed
• Cannabis starting material (plant material, biomass, fresh or dried flower intended for further processing)
• Cannabis-based ingredients (intermediate extracts, isolates, distillates supplied to a manufacturer)
• Finished medicinal cannabis products (oils, capsules, dried flower presented for dispensing)

What does not require a controlled drug export licence:

• CBD prescription medicines are exempt from controlled drug import and export licences. CBD is no longer treated as a controlled drug in NZ when it represents the dominant cannabinoid (THC less than 2 percent of total cannabinoids). Exporters of CBD prescription products instead operate under the standard medicines export framework administered by Medsafe.

An export licence on its own is not sufficient. You also need the underlying activity licence (Possession for Manufacture or Supply, depending on what you are exporting and how you produced it), and you need an import licence from the destination country. We cover both pieces in the next sections.

For a complete picture of the upstream activity licences that sit beneath any NZ cannabis export licence, see our breakdown of NZ medicinal cannabis licence requirements.

How Does the NZ Export Process Differ from Import?

NZ’s import and export frameworks share an instrument (the Misuse of Drugs Regulations 2019, as amended) but operate in opposite directions and with different licence triggers. Understanding both sides matters because most commercial operators eventually do both: import seed or starting material to cultivate, then export finished product or ingredients.

The import side, in summary:

• Controlled drug import licence required for cannabis seed, starting material, cannabis-based ingredients, and finished products coming into NZ.
• CBD prescription medicines exempt from controlled drug import licences (handled under standard medicines pathways).
• Regulation 38A (5 July 2024) bans personal importation of CBD products via overseas courier or mail. This was a tightening of the framework, not an expansion. Patients can no longer order CBD oil from an overseas pharmacy and have it mailed home; everything must come through a NZ-licensed supply chain.

The export side, in summary:

• Controlled drug export licence required for all cannabis material categories.
• CBD prescription medicines exempt.
• Quality standards reference the importing country, not NZ MQS.
• Seed and material export for research is now expressly permitted.

The fundamental asymmetry: imports are tighter under the 2024 amendments (Regulation 38A added a new restriction), while exports are looser (NZ MQS no longer required, starting material categories broadened). The policy intent is clear, NZ wants to be a producer-exporter, not a personal-import market. Anyone planning a NZ cannabis export licence application should treat both halves as one workflow, especially if the same product moves in and out of NZ during testing or processing.

What Quality Standards Apply to NZ Cannabis Exports?

This is the operational headline of the 2024 amendments. Pre-amendment, every export had to meet the NZ Minimum Quality Standard, which reference European Pharmacopoeia testing methods and is administered through MQS verification. Post-amendment, exports only need to meet the importing jurisdiction’s quality standards.

What that looks like in practice:

• Exporting to Germany. Meet EU GMP for the manufacturer (Medsafe certification translates well via mutual recognition with European authorities), German Federal Institute for Drugs and Medical Devices (BfArM) requirements, and the relevant German pharmacopoeia or DAB monographs. NZ MQS verification is not required for the shipment itself.
• Exporting to Australia. Meet Therapeutic Goods Administration (TGA) requirements, including TGO 93 monographs and Australian Manufacturing Principles. Again, NZ MQS verification is not required for the export.
• Exporting to the United Kingdom. Meet MHRA controlled drug requirements, BP/EP monographs as applicable, and the GMP standard recognised by MHRA.

The implications are significant. A NZ producer no longer needs to maintain two parallel quality systems (one for domestic MQS, one for the export destination). The producer can target the destination spec from the start. The cost saving is real, and the operational simplification is even larger.

What did not change: the underlying NZ GMP for manufacturing, the GACP for cultivation, and the controlled drug security requirements all still apply to the licence holder. The amendment did not deregulate cannabis production in NZ. It removed the additional layer of MQS verification on exports specifically. For domestic supply, MQS verification through Medsafe is still mandatory. See NZ Minimum Quality Standard for cannabis (MQS) for the domestic verification workflow.

For the underlying GMP and GACP requirements that still apply to all licensees, see our coverage of NZ cannabis GMP Medsafe requirements and NZ cannabis GACP cultivation requirements.

What’s the Role of the Importing Country’s Import Licence?

The MCA will only issue a NZ cannabis export licence after the destination country has issued its own import licence covering the same shipment. The sequencing is non-negotiable: the buyer’s import authorisation comes first, then NZ’s export authorisation.

The workflow looks like this:

1. Commercial agreement first. Buyer and seller agree on product, quantity, specification, delivery date, and price. The specification must reference the importing country’s quality standards, not NZ MQS.
2. Buyer applies for an import licence. The buyer (typically a licensed pharmaceutical wholesaler or manufacturer in the destination country) applies to their national competent authority. In Germany, that is BfArM. In Australia, the Office of Drug Control. In the UK, the Home Office.
3. Buyer provides the import licence to the NZ exporter. Once issued, the buyer sends the import licence to the NZ exporter. The licence specifies the exact material, quantity, and consignee.
4. NZ exporter applies for a controlled drug export licence. The NZ application references the destination import licence as the upstream authorisation. Without that, the MCA will not progress the application.
5. MCA issues the controlled drug export licence. The licence is consignment-specific, not an open-ended export permission.
6. Shipment proceeds under both licences. The shipment must match both the import and the export authorisations exactly: same material, same quantity, same consignor and consignee.

Practical takeaway: lead times for the first export to a new country are dominated by the destination’s import licence process, not the NZ side. Mature export programs maintain a buyer relationship and a renewed import licence on a rolling basis so that subsequent shipments under the same NZ cannabis export licence can move quickly.

Frequently Asked Questions

Do I need an NZ cannabis export licence to ship CBD prescription medicines overseas?

No. CBD prescription medicines are exempt from the controlled drug import and export licence regime. Where the product qualifies as a CBD prescription medicine (THC less than 2 percent of total cannabinoids and approved as a prescription medicine), it is handled under the standard Medsafe medicines export pathway, not the controlled drug regime. You still need to satisfy the destination country’s medicines import requirements, but you do not need an NZ controlled drug export licence for that specific category.

Can I export cannabis seed or starting material from NZ for research purposes?

Yes. The 5 July 2024 Amendment Regulations expressly permit export of cannabis seed, starting material, and cannabis-based ingredients for testing, analysis, or research. This was effectively closed before the amendments. You still need a controlled drug export licence and an import authorisation from the destination country (or its research-licence equivalent), but the legal pathway now exists. Read more in the Amendment Regulations 2024.

If exports do not need to meet NZ MQS, do I still need MQS verification at all?

For exports specifically, no. For domestic supply within NZ, MQS verification remains mandatory and is verified by Medsafe before a product can be supplied to NZ patients. Most commercial operators target both markets, so they maintain MQS verification for the domestic line and tailor each export line to its destination spec. Operators that only export can in theory skip MQS verification, but the controlled drug security, NZ GMP, and GACP requirements on the licence itself still apply regardless of where the product ships.

What was the old export situation before July 2024?

Pre-amendment, NZ exports were technically permitted but commercially impractical. Every exported product had to meet NZ MQS in addition to the destination country’s standards, which often meant double testing and double documentation. Starting material categories were narrow, and seed/research exports were not clearly authorised. The Pre-Scheme vs. Current Scheme comparison in the full guide describes the change as Export going from “Not commercially viable” to “Enabled; only importing country’s standards required”. The Amendment Regulations 2024 are the legal instrument that made the change.

Get the Full NZ Medicinal Cannabis Compliance Checklist

Everything in this article on NZ cannabis export licences, plus the full five licence activity types, GACP cultivation requirements, GMP Medsafe compliance, MQS verification workflow, and a printable 31 December stocktake template. Built for compliance officers, QAPs, and licence applicants in the NZ Medicinal Cannabis Scheme.

Download Free Guide